FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer ...Middle East

Medscape - News
The phase 3 data showed a 2-month progression-free survival benefit with elacestrant versus fulvestrant or an aromatase inhibitor. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer )

Apple Storegoogle play

Also on site :